Source comparison
BPC-157 vs Conventional SIBO Treatments: Context and Limitations
Rifaximin (antibiotic) Direct bacterial killing via RNA polymerase inhibition 10–14 days 50–60% negative breath test at 3 months None. May worsen barrier if dysbiosis induced Gold standard for hydrogen-dominant SIBO, minimal systemic absorption, but relapse co
This comparison does not assign a generated winner or score.
- Rifaximin (antibiotic)
- Direct bacterial killing via RNA polymerase inhibition
- 10–14 days
- 50–60% negative breath test at 3 months
- None. May worsen barrier if dysbiosis induced
- Gold standard for hydrogen-dominant SIBO, minimal systemic absorption, but relapse common without motility correction
- Herbal antimicrobials (berberine, oregano oil, neem)
- Broad-spectrum antimicrobial through membrane disruption
- 4–6 weeks
- 45–55% negative breath test (comparable to rifaximin per 2014 Global Advances study)
- Minimal. Anti-inflammatory properties secondary
- Lower cost than rifaximin, broader microbial coverage including methane-producers, but quality variation between products
- Elemental diet
- Nutrient absorption proximal to bacterial overgrowth, 'starving' distal bacteria
- 14–21 days
- 80–85% negative breath test (highest single-intervention rate)
- Temporary mucosal rest allows passive healing but no active repair signalling
- Most effective single intervention but difficult to maintain, expensive, and requires medical supervision
- Prokinetics (low-dose erythromycin, prucalopride, ginger)
- Restore migrating motor complex function to prevent bacterial stasis
- Ongoing maintenance
- No direct clearance. Prevents recurrence
- None
- Essential for relapse prevention in motility-driven SIBO but ineffective as monotherapy
- BPC-157
- Gut barrier repair via growth factor upregulation and tight junction stabilisation
- 4–8 weeks
- None. Not antimicrobial
- Animal data shows accelerated mucosal healing and reduced permeability
- Theoretical adjunct value in barrier dysfunction but lacks human SIBO-specific trials. Use alongside antimicrobials, not as replacement